Pharma News

Sanofi announced on Monday plans to invest approximately €1 billion (equivalent to $1.05 billion) to build a new insulin production base in Beijing. This move will represent the French pharmaceutical giant's largest single investment in China to date.

According to the latest monitoring data, at least 19 pharmaceutical companies globally announced layoffs or business streamlining plans in November.

Recently, Zhejiang Anglikang Pharmaceutical Co., Ltd. has completed the filing and public announcement for a project to produce 4,105 tons of D(-)-Hydroxyphenylglycine Methyl Ester and 1,230 tons of D(-)-Phenylglycine Hydrochloride.

On December 2, 2024, Merck's combination antibiotic injection, Imipenem/Cilastatin/Relebactam (containing 500mg imipenem, 500mg cilastatin, and 250mg relebactam), received marketing approval from China's National Medical Products Administration.

Recently, AstraZeneca announced a significant personnel adjustment on its official website, appointing Bob Li, an Asian scientist from the Memorial Sloan Kettering Cancer Center (MSK) in the U.S., as the new head of global medical affairs in oncology.

In November, the pharmaceutical industry experienced significant changes in executive personnel, with adjustments at several well-known domestic and international enterprises drawing widespread attention.

Eli Lilly reported total revenue of $31.5 billion for the first three quarters of the year, reflecting a 27% year-on-year increase, driven by strong performances from Tirzepatide and Semaglutide, which together generated over $20 billion in sales.

Cassava Sciences announced on November 25, 2024, that its Phase III ReThink-ALZ study failed to meet primary and secondary endpoints for treating mild to moderate Alzheimer's disease.

Amgen announced that its weight loss therapy, MariTide, achieved positive results in a Phase II clinical study over 52 weeks, showing an average weight loss of about 20% in non-diabetic obese or overweight individuals, without a weight plateau.

On November 26, 2024, Pfizer announced a strategic cooperation with China Resources Pharmaceutical Commercial to manage the commercialization of four oncology treatments in China.

Lyfius Pharma Pvt Ltd, a manufacturer of penicillin G, announced the launch of its state-of-the-art manufacturing facility in Kakinada, Andhra Pradesh, on October 29th. The company has invested 25 billion rupees in the plant, which has an annual producti

In a recent business development, Yuhan Corporation, a well-known pharmaceutical company in South Korea, announced that it has entered into an important cooperation agreement with Gilead Sciences, a world-renowned biopharmaceutical company.

The Biden administration on Tuesday formally announced a new rule aimed at making weight-loss drugs covered by Medicare and Medicaid for the benefit of obese patients. The publication of the proposal heralds easier access to weight-loss drugs such as Wego

On November 19, Merck announced key Phase 3 positive results from the MK-2475A-D77 clinical trial (NCT05722015). The results of this study indicate that in the field of first-line treatment of non-small cell lung cancer, the combination of subcutaneous K

Jazz Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved Zanidatamab, a bi-specific antibody drug developed in collaboration with Zymeworks for the HER2 target.

Bayer partnered with Hua Medicine in 2020 to commercialize its hypoglycemic drug doglietine in China, aiming to mitigate the risk of gathering its core hypoglycemic drug bitangpin.

Traditional large pharmaceutical companies Hengrui Pharmaceutical and Stone Pharmaceutical Group, which have made remarkable achievements in research and development and business expansion, experienced a significant decline in profitability in the third q

On November 22, 2024, the official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration announced that the marketing application for Tezeliumab injection jointly submitted by AstraZeneca and Amgen has been

On November 21, 2024, Bayer announced that a Supplemental New Drug Application (sNDA) for its product darotamine (trade name: Nubeqa) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive pr

On November 17, 2024, the Financial Times reported that Danish pharmaceutical giant Novo Nordisk plans to publish final clinical trial data for its new generation weight loss drug CagriSema next month. According to Novo Nordisk, the results of the trial w